Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.
about
Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Beyond H&E: integration of nucleic acid-based analyses into diagnostic pathology.Use of neutrophil to lymphocyte ratio for predicting histopathological grade of canine mast cell tumours.A prospective evaluation of the impact of second-opinion histopathology on diagnostic testing, cost and treatment in dogs and cats with cancer.The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours.Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours.c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.Association of prognostic features and treatment on survival time of dogs with systemic mastocytosis: A retrospective analysis of 40 dogs.Intramuscular mast cell tumors in 7 dogs.Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures.Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas.c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.Canine oral mucosal mast cell tumours.
P2860
Q33726782-64D84A28-6136-470C-945E-C70E078295B8Q35017911-29EF81BB-7CC5-46AE-822F-8B8C0CBEB8F1Q36138856-AFA78F3D-240C-4F0F-9C2A-683F8E864B49Q38082814-ED749447-8DB6-4FA1-91EC-174CD4F065DFQ43727603-43AB3134-05DD-4C39-A6BE-40BAA481259AQ47417940-F7D46A12-DA3F-4028-9E58-108C3ACFD92EQ47742852-E2A7D161-3143-494A-BDB7-69BB76A24647Q48196847-81CD3757-5850-4D25-84A9-0075B4A62446Q49851905-2D63FE10-B40D-47FD-B717-2B3D533CC7C2Q50212157-16BEECE9-EC06-4E18-A2C4-2C5678A2BE09Q50241634-C04EA444-560A-466D-A46D-D9FD3FDB9C9FQ54171136-92EF8BD0-8133-46ED-974E-AEC4344DBD64Q54322229-9379885F-B727-46FF-9E47-66DBD9EF2DC4Q54397980-9D7A402F-F415-40EC-91BE-5392D601707F
P2860
Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Evaluation of prognostic marke ...... th vinblastine and prednisone.
@ast
Evaluation of prognostic marke ...... th vinblastine and prednisone.
@en
type
label
Evaluation of prognostic marke ...... th vinblastine and prednisone.
@ast
Evaluation of prognostic marke ...... th vinblastine and prednisone.
@en
prefLabel
Evaluation of prognostic marke ...... th vinblastine and prednisone.
@ast
Evaluation of prognostic marke ...... th vinblastine and prednisone.
@en
P2093
P2860
P356
P1476
Evaluation of prognostic marke ...... th vinblastine and prednisone.
@en
P2093
Douglas H Thamm
Elizabeth Hamilton
Joshua D Webster
Matti Kiupel
Vilma Yuzbasiyan-Gurkan
P2860
P2888
P356
10.1186/1746-6148-4-32
P577
2008-08-13T00:00:00Z
P5875
P6179
1029148493